Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK2 | Q9NRA0 | 7/20 | 0.64 |
| ▸ | SPHK1 | Q9NYA1 | 7/20 | 0.64 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.50 |
| ▸ | L3MBTL3 | Q96JM7 | 6/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.48 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.48 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4804888 | 1.00 | SPHK2 (0.64) | SPHK2SPHK1HRH3L3MBTL3L3MBTL1 | |
| SCHEMBL4807164 | 0.91 | SPHK2 (0.60) | SPHK2SPHK1HRH3L3MBTL3L3MBTL1 | |
| SCHEMBL4807172 | 0.91 | SPHK2 (0.60) | SPHK2SPHK1HRH3L3MBTL3L3MBTL1 | |
| SCHEMBL15921347 | 0.82 | SPHK2 (0.71) | SPHK2SPHK1HRH3 | |
| SCHEMBL15921348 | 0.82 | SPHK2 (0.71) | SPHK2SPHK1HRH3 | |
| SCHEMBL4889834 | 0.82 | SPHK2 (0.67) | SPHK2SPHK1HRH3SIGMAR1 | |
| SCHEMBL4889839 | 0.82 | SPHK2 (0.67) | SPHK2SPHK1HRH3SIGMAR1 | |
| SCHEMBL8879669 | 0.82 | SPHK2 (0.67) | SPHK2SPHK1HRH3SIGMAR1 | |
| SCHEMBL27627908 | 0.82 | SPHK2 (0.66) | SPHK2SPHK1HRH3 | |
| SCHEMBL6797294 | 0.81 | SPHK2 (0.62) | SPHK2SPHK1HRH3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7320973-B2 | Dihydrodiaryloxazepine derivative and pharmaceutical composition containing the same | AJINOMOTO CO., INC. (JP) | 2008-01-22 | — | — | US | disclosed |
| US-20040110742-A1 | Dihydrodiaryloxazepine derivative and pharmaceutical composition containing the same | AJINOMOTO CO., INC. (JP) | 2004-06-10 | — | — | US | disclosed |
| EP-1403258-A1 | DIHYDRODIARYLOXAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110742-A1 | Dihydrodiaryloxazepine derivative and pharmaceutical composition containing the same | CYP3A4, PPARD, CYP4B1 | SPHK2 697/4885SPHK1 792/4885HRH3 518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.